Pharma News, 2022

Moleculin Biotech’s WP1122 has gained Fast Track status from the FDA for the treatment of glioblastoma multiforme, an aggressive cancer that occurs in the brain or spine. ...

As Roche heads towards an FDA verdict on its CD20xCD3 bispecific Lunsumio for lymphoma before the end of this year, rivals from Regeneron and AbbVie are starting to nip at its heels, with new clini...

The San Antonio Breast Cancer Symposium (SABCS) has highlighted some of the most promising clinical research being undertaken by drugmakers in the category, with AstraZeneca leading the charge with...

The FDA has granted Fast Track status to UK-based Istesso’s BS2320 drug candidate for the treatment of patients with idiopathic pulmonary fibrosis (IPF), a chronic disease that causes lung scarri...

A federal judge has decided consumer claims that Zantac (ranitidine) causes cancer were not backed by scientific evidence, and thus several big drugmakers can now avoid thousands of U.S. lawsuits....

The European Commission (EC) has approved Takeda’s dengue Qdenga vaccine for individuals four years and older in preventing dengue, a mosquito-borne disease that can cause severe bleeding and sho...

The state of Colorado has submitted its proposed plan to the FDA seeking the agency’s approval to import prescription drugs from Canada.

The coronavirus pandemic interrupted efforts to control malaria, resulting in 63,000 additional deaths and 13 million more infections globally over two years, according to a report from the World H...

The FDA has granted a priority review to Pfizer’s Biologics License Application for its vaccine candidate RSVpreF for respiratory syncytial virus (RSV)-associated lower respiratory tract disease ...

In the United States, Orphan Drug designation is granted to drugs or biologics intended to treat, diagnose, or prevent rare diseases or conditions. 

Olutasidenib (Rezlidhia) is indicated for adult patients with relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation detected by an FDA-approved test. ...

The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine discussed the treatment differences and unmet needs between dementia with Lewy bodies ...